Mometasone and Markers of Airway Inflammation

The Effects of Mometasone on Markers of Airway Inflammation

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00711165

Enrollment

Registered

2008-07-08

Start date

2005-08-31

Completion date

2006-08-31

Last updated

2008-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, Nitric Oxide, Exhaled Breath Condensate, Methacholine Challenge

Brief summary

A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.

Detailed description

Patients with asthma and not treated with anti-inflammatory medications were studied. This was a parallel, randomized, placebo-controlled study to investigate the effects of Asmanex on markers of airway inflammation including exhaled nitric oxide, airway reactivity, FEV1 and nitrates/nitrites and pH in exhaled breath condensate.

Interventions

DRUGPlacebo

2 puffs, qd

DRUGMometasone Furoate

400 mcg, qd for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Asthma * non-smoker * FEV1 of at least 60% predicted

Exclusion criteria

* Pregnancy or lactation * Corticosteroid use in past 30 days

Design outcomes

Primary

Measure	Time frame
Exhaled Nitric Oxide	8 weeks

Secondary

Measure	Time frame
Airway Reactivity	8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026